The Interface between the EGF2 Domain and the Protease Domain in Blood Coagulation Factor IX Contributes to Factor VIII Binding and Factor X Activation

Biochemistry ◽  
2006 ◽  
Vol 45 (35) ◽  
pp. 10777-10785 ◽  
Author(s):  
Caroline Fribourg ◽  
Alexander B. Meijer ◽  
Koen Mertens
1988 ◽  
Vol 7 (5) ◽  
pp. 613-632
Author(s):  
John M. Beals ◽  
Joseph Weber ◽  
Paul Derwent ◽  
Kenneth L. Grant ◽  
Francis J. Castellino

1995 ◽  
Vol 270 (25) ◽  
pp. 14884-14890 ◽  
Author(s):  
Peter J. Lenting ◽  
Hans ter Maat ◽  
Patrick P. F. M. Clijsters ◽  
Marie-José S. H. Donath ◽  
Jan A. van Mourik ◽  
...  

1981 ◽  
Vol 45 (01) ◽  
pp. 055-059 ◽  
Author(s):  
B Østerud ◽  
C K Kasper ◽  
K K Lavine ◽  
C Prodanos ◽  
S I Rapaport

SummaryAn abnormal blood coagulation factor IX has been isolated from the blood of a hemophilia B patient with a variant of the disease (hemophilia Bm) characterized by a normal concentration of factor IX antigen, negligible factor IX coagulant activity, and a prolonged prothrombin time with bovine tissue factor. The isolated protein (factor IXBm) had the same apparent molecular weight as normal factor IX (55,000) and the same mobility on two dimensional immunoelectrophoresis as normal factor IX. Factor IXBm underwent limited proteolysis induced by activated factor XI, in the presence of Ca2+ ions, or induced by the reaction product of tissue factor, factor VII and Ca2+ ions. A timecourse study showed that activated factor XI cleaved factor IXBm and factor IX at similar rates. However, in contrast to normal factor IX, the limited protelysis of factor IXBm did not generate procoagulant activity.In kinetic experiments purified factor IXBm behaved like a competitive inhibitor (Ki of 0.017 μM) of the activation of factor X by bovine tissue factor and factor VII. Normal factor IX was also found to inhibit the reaction but required a four-fold higher concentration to achieve the same inhibitory effects as factor IXBm.


Sign in / Sign up

Export Citation Format

Share Document